Information Provided By: 
Fly News Breaks for February 10, 2017
NUVA
Feb 10, 2017 | 07:28 EDT
Canaccord analyst Kyle Rose raised his price target on NuVasive to $82 from $69 following solid Q4 results. The analyst noted revenues outperformed across all segments as the company's core U.S. implants business continues to grow at twice the rate of the broader market. Rose views the company's guidance as conservative and sees upside to both revenues and earnings in the second half of the year. Rose reiterated his Buy rating on NuVasive shares.
News For NUVA From the Last 2 Days
There are no results for your query NUVA
